Guggenheim lowered the firm’s price target on Danaher (DHR) to $250 from $275 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for several companies in its Diagnostics and Life Sciences Tools coverage to reflect recent updates from the companies after meetings with management teams.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Investors should buy Codexis following contract news, says Craig-Hallum
- FedEx downgraded, Adobe upgraded: Wall Street’s top analyst calls
- Morning Movers: FedEx, Nike headline dip in corporate outlooks
- Danaher upgraded to Buy from Neutral at Goldman Sachs
- Chipotle upgraded, Charter initiated: Wall Street’s top analyst calls